Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
2014 ASH Annual MeetingHagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.
Related Videos
Richard M. Stone, MD, on the SWOG S1117 Study
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “...
Linda J. Burns, MD, on the BLAST Study
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379,
Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...
Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma
Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituxima...
Richard M. Stone, MD, on the UK NCRI AML17 Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7,
